Why does rotavirus vaccine effectiveness vary around the globe?
- 1Baker Institute for Animal Health, Cornell University, Ithaca, New York, United States of America
- 2Department of Microbiology and Immunology, College of Veterinary Medicine, Cornell University, Ithaca, New York, United States of America
Abstract
Rotavirus vaccines have transformed the prevention of severe childhood diarrhea globally, yet their effectiveness remains markedly lower in low- and middle-income countries (LMICs), where rotavirus mortality is greatest. Understanding the biological and environmental determinants of this disparity is critical for optimizing existing vaccination strategies and informing next-generation vaccine development. This review examines the factors contributing to variable rotavirus vaccine effectiveness across different settings, with a focus on maternal antibodies, infant gut health, co-infections, co-vaccinations and human genetic polymorphisms. Maternal antibodies, transferred transplacentally and through breast milk, can inhibit vaccine replication in the infant gut. Maternal antibody interference may be exacerbated in LMICs due to higher maternal antibody levels, driven by increased rates of natural rotavirus exposure and prolonged breastfeeding. Malnutrition, disruption of the gut microbiome, and environmental enteric dysfunction collectively impair intestinal immune responses, with their relative contributions also varying by geography. Co-administration of the oral poliovirus vaccine and concurrent enteric infections represent additional sources of interference that are more prevalent in resource-limited settings. Host genetic factors, particularly polymorphisms in fucosyltransferase genes governing histo-blood group antigen expression, further modulate vaccine immunogenicity across populations. These factors do not act in isolation; rather, they interact to shape the gut environment and collectively limit oral vaccine replication. Addressing rotavirus vaccine inequity will require context-specific strategies that combine optimized vaccine scheduling, nutritional and microbiome-targeted interventions, and the development of novel vaccine platforms capable of overcoming the unique immunological challenges of LMICs.
Related
- Pheromone and morphometric features of honey bee (Apis mellifera) queens imported to Canada from around the globe
- Prevalence and genotype distribution of norovirus and rotavirus among children under five with diarrheal infection in lower-middle-income countries after Rotavirus vaccine introduction: A systematic review and meta-analysis
- Mathematical AI Predicts 40% and 57% Influenza Vaccine Effectiveness Against H1N1 and H3N2, Respectively, for the 2026--2027 U.S. Season
- Does the method matter? Evaluating the effectiveness, efficiency and ease of hearing-aid gain self-adjustment
- Evaluating the impact and cost-effectiveness of typhoid conjugate vaccine schedules across diverse settings: A multi-model comparison
BibTeX
@article{woodyear2026does,
title = {{Why does rotavirus vaccine effectiveness vary around the globe?}},
author = {Sarah Woodyear and Nabila Nawar Binti and Sarah L. Caddy},
journal = {PLOS Pathogens},
year = {2026},
month = oct,
doi = {10.1371/journal.ppat.1014670},
url = {https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1014670},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Why does rotavirus vaccine effectiveness vary around the globe?
AU - Sarah Woodyear
AU - Nabila Nawar Binti
AU - Sarah L. Caddy
PY - 2026
DA - 2026/10/09
JO - PLOS Pathogens
DO - 10.1371/journal.ppat.1014670
UR - https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1014670
AB - Rotavirus vaccines have transformed the prevention of severe childhood diarrhea globally, yet their effectiveness remains markedly lower in low- and middle-income countries (LMICs), where rotavirus mortality is greatest. Understanding the biological and environmental determinants of this disparity is critical for optimizing existing vaccination strategies and informing next-generation vaccine development. This review examines the factors contributing to variable rotavirus vaccine effectiveness across different settings, with a focus on maternal antibodies, infant gut health, co-infections, co-vaccinations and human genetic polymorphisms. Maternal antibodies, transferred transplacentally and through breast milk, can inhibit vaccine replication in the infant gut. Maternal antibody interference may be exacerbated in LMICs due to higher maternal antibody levels, driven by increased rates of natural rotavirus exposure and prolonged breastfeeding. Malnutrition, disruption of the gut microbiome, and environmental enteric dysfunction collectively impair intestinal immune responses, with their relative contributions also varying by geography. Co-administration of the oral poliovirus vaccine and concurrent enteric infections represent additional sources of interference that are more prevalent in resource-limited settings. Host genetic factors, particularly polymorphisms in fucosyltransferase genes governing histo-blood group antigen expression, further modulate vaccine immunogenicity across populations. These factors do not act in isolation; rather, they interact to shape the gut environment and collectively limit oral vaccine replication. Addressing rotavirus vaccine inequity will require context-specific strategies that combine optimized vaccine scheduling, nutritional and microbiome-targeted interventions, and the development of novel vaccine platforms capable of overcoming the unique immunological challenges of LMICs.
SN - 1553-7374
ER -